Roxatidine
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Roxatidine acetate is a specific and competitive histamine H2 receptor antagonist drug that is used to treat gastric ulcers, Zollinger–Ellison syndrome, erosive esophagitis, gastro-oesophageal reflux disease, and gastritis.[1][2]
Pharmacodynamic studies showed that 150 mg of roxatidine acetate were optimal in suppressing gastric acid secretion, and that a single bedtime dose of 150 mg was more effective than a dose of 75 mg twice daily in terms of inhibiting nocturnal acid secretion.[1]
It is available in countries including China, Japan, Korea, Germany, Italy, the Netherlands, Greece and South Africa.[2]
References
- ↑ 1.0 1.1 Murdoch D, McTavish D (1991). “Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders”. Drugs. 42 (2): 240–260. doi:10.2165/00003495-199142020-00006. PMID 1717223.
- ↑ 2.0 2.1 BioSpectrum Bureau 1 November 2012 Sinhuan’s generic heart drug gets production approval
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH